• Je něco špatně v tomto záznamu ?

Oncogenic Fusions in Gliomas: An Institutional Experience

J. Polivka, M. Svajdler, V. Priban, J. Mracek, P. Kasik, P. Martinek, N. Ptakova, M. Sharif Bagheri, D. Shetti, M. Pesta, P. Potuznik, O. Topolcan

. 2022 ; 42 (4) : 1933-1939. [pub] -

Jazyk angličtina Země Řecko

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc22018903

BACKGROUND/AIM: Gliomas are primary malignancies of the central nervous system (CNS). High-grade gliomas are associated with poor prognosis and modest survival rates despite intensive multimodal treatment strategies. Targeting gene fusions is an emerging therapeutic approach for gliomas that allows application of personalized medicine principles. The aim of this study was to identify detectable fusion oncogenes that could serve as predictors of currently available or newly developed targeted therapeutics in cross-sectional samples from glioma patients using next-generation sequencing (NGS). PATIENTS AND METHODS: A total of 637 patients with glial and glioneuronal tumours of the CNS who underwent tumour resection between 2017 and 2020 were enrolled. Detection of fusion transcripts in FFPE tumour tissue was performed by a TruSight Tumour 170 assay and two FusionPlex kits, Solid Tumour and Comprehensive Thyroid and Lung. RESULTS: Oncogene fusions were identified in 33 patients. The most common fusion was the KIAA1549-BRAF fusion, detected in 13 patients, followed by FGFR fusions (FGFR1-TACC1, FGFR2-CTNNA3, FGFR3-TACC3, FGFR3-CKAP5, FGFR3-AMBRA1), identified in 10 patients. Other oncogene fusions were also infrequently diagnosed, including MET fusions (SRPK2-MET and PTPRZ1-MET) in 2 patients, C11orf95-RELA fusions in 2 patients, EGFR-SEPT14 fusion in 2 patients, and individual cases of SRGAP3-BRAF, RAF1-TRIM2, EWSR1-PALGL1 and TERT-ALK fusions. CONCLUSION: The introduction of NGS techniques provides additional information about tumour molecular alterations that can aid the multimodal management of glioma patients. Patients with gliomas positive for particular targetable gene fusions may benefit from experimental therapeutics, enhancing their quality of life and prolonging survival rates.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc22018903
003      
CZ-PrNML
005      
20220804135156.0
007      
ta
008      
220720s2022 gr f 000 0|eng||
009      
AR
024    7_
$a 10.21873/anticanres.15671 $2 doi
035    __
$a (PubMed)35347013
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a gr
100    1_
$a Polivka, Jiri $u Department of Histology and Embryology, Faculty of Medicine in Pilsen, Charles University, Pilsen, Czech Republic $u Biomedical Center, Faculty of Medicine in Pilsen, Charles University, Pilsen, Czech Republic $u Department of Neurology, University Hospital Pilsen, Pilsen, Czech Republic
245    10
$a Oncogenic Fusions in Gliomas: An Institutional Experience / $c J. Polivka, M. Svajdler, V. Priban, J. Mracek, P. Kasik, P. Martinek, N. Ptakova, M. Sharif Bagheri, D. Shetti, M. Pesta, P. Potuznik, O. Topolcan
520    9_
$a BACKGROUND/AIM: Gliomas are primary malignancies of the central nervous system (CNS). High-grade gliomas are associated with poor prognosis and modest survival rates despite intensive multimodal treatment strategies. Targeting gene fusions is an emerging therapeutic approach for gliomas that allows application of personalized medicine principles. The aim of this study was to identify detectable fusion oncogenes that could serve as predictors of currently available or newly developed targeted therapeutics in cross-sectional samples from glioma patients using next-generation sequencing (NGS). PATIENTS AND METHODS: A total of 637 patients with glial and glioneuronal tumours of the CNS who underwent tumour resection between 2017 and 2020 were enrolled. Detection of fusion transcripts in FFPE tumour tissue was performed by a TruSight Tumour 170 assay and two FusionPlex kits, Solid Tumour and Comprehensive Thyroid and Lung. RESULTS: Oncogene fusions were identified in 33 patients. The most common fusion was the KIAA1549-BRAF fusion, detected in 13 patients, followed by FGFR fusions (FGFR1-TACC1, FGFR2-CTNNA3, FGFR3-TACC3, FGFR3-CKAP5, FGFR3-AMBRA1), identified in 10 patients. Other oncogene fusions were also infrequently diagnosed, including MET fusions (SRPK2-MET and PTPRZ1-MET) in 2 patients, C11orf95-RELA fusions in 2 patients, EGFR-SEPT14 fusion in 2 patients, and individual cases of SRGAP3-BRAF, RAF1-TRIM2, EWSR1-PALGL1 and TERT-ALK fusions. CONCLUSION: The introduction of NGS techniques provides additional information about tumour molecular alterations that can aid the multimodal management of glioma patients. Patients with gliomas positive for particular targetable gene fusions may benefit from experimental therapeutics, enhancing their quality of life and prolonging survival rates.
650    _2
$a adaptorové proteiny signální transdukční $x genetika $7 D048868
650    _2
$a průřezové studie $7 D003430
650    12
$a gliom $x genetika $x patologie $7 D005910
650    _2
$a lidé $7 D006801
650    _2
$a proteiny asociované s mikrotubuly $x genetika $7 D008869
650    12
$a onkogenní fúze $7 D050596
650    _2
$a onkogeny $x genetika $7 D009857
650    _2
$a protein-serin-threoninkinasy $7 D017346
650    _2
$a kvalita života $7 D011788
650    _2
$a tyrosinfosfatasy receptorového typu, třída 5 $x genetika $7 D054633
655    _2
$a časopisecké články $7 D016428
700    1_
$a Svajdler, Marian $u Sikl's Department of Pathology, University Hospital Pilsen, Pilsen, Czech Republic; svajdlerm@fnplzen.cz $u Biopticka laboratory s.r.o, Pilsen, Czech Republic $u Cytopathos, s.r.o., Bratislava, Slovak Republic
700    1_
$a Priban, Vladimir $u Department of Neurosurgery, University Hospital Pilsen, Pilsen, Czech Republic
700    1_
$a Mracek, Jan $u Department of Neurosurgery, University Hospital Pilsen, Pilsen, Czech Republic
700    1_
$a Kasik, Petr $u Department of Neurosurgery, University Hospital Pilsen, Pilsen, Czech Republic
700    1_
$a Martinek, Petr $u Biopticka laboratory s.r.o, Pilsen, Czech Republic
700    1_
$a Ptakova, Nikola $u Biopticka laboratory s.r.o, Pilsen, Czech Republic
700    1_
$a Sharif Bagheri, Mahyar $u Department of Biology, Faculty of Medicine in Pilsen, Charles University, Pilsen, Czech Republic
700    1_
$a Shetti, Dattatrya $u Department of Histology and Embryology, Faculty of Medicine in Pilsen, Charles University, Pilsen, Czech Republic
700    1_
$a Pesta, Martin $u Department of Biology, Faculty of Medicine in Pilsen, Charles University, Pilsen, Czech Republic
700    1_
$a Potuznik, Pavel $u Department of Neurology, University Hospital Pilsen, Pilsen, Czech Republic
700    1_
$a Topolcan, Ondrej $u Department of Immunochemical Diagnostics, University Hospital Pilsen, Pilsen, Czech Republic
773    0_
$w MED00000478 $t Anticancer research $x 1791-7530 $g Roč. 42, č. 4 (2022), s. 1933-1939
856    41
$u https://pubmed.ncbi.nlm.nih.gov/35347013 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20220720 $b ABA008
991    __
$a 20220804135149 $b ABA008
999    __
$a ok $b bmc $g 1822478 $s 1170146
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2022 $b 42 $c 4 $d 1933-1939 $e - $i 1791-7530 $m Anticancer research $n Anticancer Res $x MED00000478
LZP    __
$a Pubmed-20220720

Najít záznam

Citační ukazatele

Možnosti archivace